Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

Background The addition of monoclonal antibody therapy against GD2 to the treatment of high-risk neuroblastoma led to improved responses in patients. Nevertheless, administration of GD2 antibodies against neuroblastoma is associated with therapy-limiting neuropathic pain. This severe pain is evoked...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefan Nierkens, Niels Eijkelkamp, Maaike Nederend, Jeanette Leusen, Mitchell Evers, Marjolein Stip, Kaylee Keller, Hanneke Willemen, Marco Jansen, Chilam Chan, Kevin Budding, Thomas Valerius, Friederike Meyer-Wentrup
Format: Article
Language:English
Published: BMJ Publishing Group 2021-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/10/e003163.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/9/10/e003163.full

Similar Items